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Abstract
Purpose To describe a case of retrobulbar optic neuritis that
presented within 3 weeks of adalimumab treatment initiation.
Methods This index case was evaluated with visual field
testing, brain magnetic resonance imaging, lumbar puncture,
and laboratory evaluation, and treated with intravenous
methylprednisolone followed by a steroid taper.
Results Our patient made a full visual recovery, but was
found to have extensive T2/FLAIR foci of hyperintensities
that enhanced and had restricted diffusion on magnetic
resonance imaging (MRI). Six months later, these demye-
linating lesions still persisted and our patient was initiated
on immunomodulatory treatment.
Conclusion With the extensive burden of disease at presen-
tation and persistence of lesions on follow-up MRI, this
unusual case seems to suggest an unmasking of an underly-
ing demyelinating process by adalimumab. The clinician
should be mindful of this association and monitor for any
manifestations and treat appropriately.
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Introduction
This report describes a case of adalimumab associated retro-
bulbar optic neuritis, of which two cases have been reported
thus far in the literature [1]. Adalimumab is a recombinant
monoclonal antibody that binds to the cytokine tumor ne-
crosis factor (TNFα). Various demyelinating disorders such
as optic neuritis, multiple sclerosis, transverse myelitis, and
Guillain–Barré have been reported in association with
TNFα antagonist therapy [2–4].
Case report
The patient is a 42-year-old African-American female with a
20-year history of a chronic idiopathic non-granulomatous
anterior uveitis. Her medical history includes hypertension
and genital and oral herpes, for which she was maintained
on valcyclovir. Her previous evaluations for the uveitis
included non-reactive FTA-ABS and RPR, negative tuber-
culin skin test, negative serologies of ANCA, ANA, anti-
double stranded DNA, rheumatoid factor, Lyme EIA, and
normal ACE level, gallium scan and chest X-ray.
Biweekly adalimumab 40 mg injections were initiated
because of persistent inflammation of her right eye, de-
spite being treated with steroid-sparing agents, metho-
trexate then mycophenalote mofetil. Four days after
receiving her second injection, she presented with “fuzzy
vision” of her right eye. Her visual acuity was reduced to
20/50 with a small right relative afferent pupillary defect,
dyschromatopsia, and no pain with movement. Her fun-
dus examination revealed an optic nerve without edema
or hemorrhage. Formal visual field testing demonstrated
a right superior altitudinal field defect. A brain and
orbital magnetic resonance imaging (MRI) with gadolin-
ium showed multiple callosal, pericallosal, periventricu-
lar, subcortical, right cerebellar lobe, and left occipital
lobe T2/FLAIR lesions with enhancement and restricted
diffusion (Fig. 1). Her vision declined to counting fingers
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and she received methylprednisolone 1 g/day for 3 days
followed by a tapering course of prednisone. A lumbar
puncture was performed; the CSF was clear and positive
for oligoclonal bands. IgG index was elevated to 13.7
(0.8–7.7). Further laboratory evaluation was negative for
HTLV I/II, HIV, and HCV antibodies, HBcAg and sAg,
Lyme titers and non-reactive to RPR. Her extended re-
view of systems and the remainder of her neurologic
examination were unremarkable.
Within a few weeks, she experienced complete reso-
lution and subsequent follow-up visual fields have been
full. Six months afterwards, repeat imaging demonstrated
no significant interval change in the multiple T2/FLAIR
foci of hyperintensities. Several of the lesions still had
faint restricted diffusion. Our patient has remained symp-
tom free and has started on immunomodulatory therapy.
Discussion
Since the introduction of TNFα antagonists into clinical use
in 1998, three TNFα antagonists have been approved: two
recombinant human monoclonal antibodies adalimumab and
infliximab and a soluble receptor etanercept. TNFα antago-
nists have been found to be efficacious in the treatment of
many immune mediated inflammatory diseases, including
rheumatoid arthritis, polyarticular juvenile rheumatoid ar-
thritis, Crohn's disease, psoriatic arthritis, and ankylosing
spondylitis.
TNFα is a cytokine secreted by T-cells and macrophages
that is an important component in the immune-mediation of
demyelination. In vivo and in vitro experiments have sug-
gested a correlative relationship between elevated TNFα
and the severity of demyelinating disease [5]. The effect of
TNF inhibition was investigated in murine experimental
autoimmune encephalitis (EAE) and the initial results were
promising [6–9]. However, neutralization of TNFα in
humans did not result in an improvement in demyelinative
disease in multiple sclerosis, but rather it seemed to exacer-
bate it [10, 11]. Several explanations of its failure in humans
include the inability of the TNFα inhibitor to penetrate the
blood brain barrier and the complex role that TNFα plays in
remyelination and regulation of other cytokines and lym-
phocytes [12].
Chung et al. [1] first described two cases of adalimumab
associated optic neuritis. Subsequently, Simsek et al. [13]
reviewed 15 cases of all TNFα antagonist associated optic
neuritis in the literature. The interval from the initial admin-
istration to presentation ranged from 2 months to 1.5 years
(median 7.5 months). All but one were treated with pulse
steroids followed by oral steroids. Nine of the 15 patients
had a complete visual recovery. Of the eight patients who
had a brain MRI reported, only two had findings suggestive
of demyelination. After 4 to 6 months, the two with signif-
icant MRI findings had only partial visual recovery.
Conclusion
It has been postulated that TNFα antagonists may induce
demyelinating events or even unmask an underlying demye-
linating process in those who are predisposed. Our patient
with her short temporal proximity to therapy initiation
and full recovery without recurrence would suggest a
causal association. The large burden of radiographic dis-
ease at presentation so quickly after treatment initiation
and its persistence would give credence to the theory that
an underlying demyelinating process was unmasked by
adalimumab.
The occurrence of a demyelinating event with TNFα
antagonist treatment is rare; however, the clinician should
be aware of the need to observe their patients closely for any
manifestations and to institute appropriate therapy.
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Fig. 1 Brain magnetic resonance imaging T2/FLAIR image
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